1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,801 | 0,821 | 05.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.08. | Lifecare ASA: Reconfirmed positive results in veterinary study support path toward market entry | 3 | Oslo Børs | ||
| 20.08. | LIFE: Lifecare ASA Q2 2025 results | 4 | Oslo Børs | ||
| LIFECARE ASA Aktie jetzt für 0€ handeln | |||||
| 13.08. | Lifecare ASA: Lifecare advances CE mark preparation for its groundbreaking medical device | 4 | Oslo Børs | ||
| 12.08. | Lifecare ASA: Invitation to presentation of Q2 2025 results 20 August at 10.45 CEST | 3 | Oslo Børs | ||
| 05.08. | Lifecare ASA Secures REK Ethics Approval For First-In-Human CGM Trial | 2 | RTTNews | ||
| 05.08. | Lifecare ASA: Lifecare receives ethics approval to initiate first-in-human trial in Norway | 3 | Oslo Børs | ||
| 08.07. | Lifecare ASA: Lifecare achieves full radio frequency compliance for CGM implant clearing the way for CE mark of electronics | 2 | Oslo Børs | ||
| 01.07. | Lifecare ASA: Lifecare advances electromagnetic compatibility compliance testing for CGM implant | 1 | Oslo Børs | ||
| 25.06. | Lifecare ASA: Share capital increase registered | 2 | Oslo Børs | ||
| 13.06. | Lifecare ASA: Final results following expiry of the exercise period for the Warrants issued in connection with the Rights Issue | 2 | Oslo Børs | ||
| 13.06. | Lifecare ASA: Notification of trade - exercise of warrants | - | Oslo Børs | ||
| 13.06. | Lifecare ASA: Last day of the Exercise Period for the Warrants issued in connection with the Rights Issue | 1 | Oslo Børs | ||
| 06.06. | Lifecare ASA: Notification of trade - exercise of warrants | 1 | Oslo Børs | ||
| 06.06. | Lifecare ASA: Last day of trading in the Warrants issued in connection with the Rights Issue | 1 | Oslo Børs | ||
| 02.06. | Lifecare ASA: Exercise price for the Warrants issued in connection with the Right Issue | 3 | Oslo Børs | ||
| 02.06. | Lifecare ASA: Commencement of the Exercise Period for the Warrants issued in connection with the Rights Issue | 2 | Oslo Børs | ||
| 30.05. | Lifecare ASA: Lifecare announces second clinical trial site at Pfützner Science & Health Institute in Mainz, Germany | 1 | Oslo Børs | ||
| 27.05. | Lifecare ASA: Lifecare appoints renowned metabolic expert Prof. Simon Dankel as Principal Investigator for upcoming clinical trial | 2 | Oslo Børs | ||
| 20.05. | Lifecare ASA: Lifecare files for human clinical trial, paving the way for CE-mark | 4 | Oslo Børs | ||
| 16.05. | Lifecare ASA: Livestream strategic update | 7 | Oslo Børs |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ROKU | 81,20 | -0,10 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 05.09.2025 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,105 | -9,48 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes | LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics ("Sernova") (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals... ► Artikel lesen | |
| BOSTON SCIENTIFIC | 91,40 | -0,22 % | Boston Scientific's Peripheral Interventions president is retiring | ||
| PAUL HARTMANN | 222,00 | -1,33 % | Januar bis Juni 2025: PAUL HARTMANN behauptet sich in herausforderndem Marktumfeld | Heidenheim (ots) - - Umsatzerlöse steigen auf 1.214,0 Mio. EUR, organisches Umsatzwachstum von 1,6 % - Bereinigtes EBITDA liegt bei 125,8 Mio. EUR, bereinigte EBITDA-Rendite bei 10,4 % - Transformationsprogramm... ► Artikel lesen | |
| SYSMEX | 11,200 | 0,00 % | Kühne+Nagel gewinnt Auftrag von Sysmex in Deutschland | ||
| ADDLIFE | 15,830 | +0,06 % | AddLife AB: Interim Report January 1 - June 30, 2025 | Continued improvement in margins and profit"The companies within AddLife continue to develop in line with our priorities. Margins are strengthening in both business areas thanks to continuous development... ► Artikel lesen | |
| EMBECTA | 12,200 | -4,69 % | Dividendenbekanntmachungen (29.08.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACNB CORPORATION US0008681092 0,34 USD 0,2911 EUR ADVANCED DRAINAGE SYSTEMS INC US00790R1041 0,18 USD 0,1541 EUR AEBI SCHMIDT HOLDING... ► Artikel lesen | |
| ENOVIS | 27,400 | -0,72 % | Enovis Corporation: Enovis Announces Second Quarter 2025 Results | Continued commercial momentum with second-quarter sales growth of 7% on a reported basisSecond-quarter Reconstructive sales grew 11% year-over-year on a reported basis Wilmington, DE, Aug. 07, 2025... ► Artikel lesen | |
| KANGJI MEDICAL | 0,930 | +0,54 % | KANGJI MEDICAL (09997): DISCLOSURE OF DEALINGS UNDER RULE 22 OF THE TAKEOVERS CODE | ||
| PULMONX | 1,490 | +0,68 % | Pulmonx korrigiert Umsatzprognose nach unten - US-Geschäft schwächelt | ||
| KOOTH | 1,750 | 0,00 % | Kooth PLC - Transfer of Treasury Shares & Exercise of Options | ||
| SI-BONE | 13,700 | +1,48 % | SI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 and Raises 2025 Guidance | Second Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $48.6 million, representing growth of 21.7%U.S. revenue of $46.4 million, representing... ► Artikel lesen | |
| PEIJIA MEDICAL | 0,825 | +2,48 % | Peijia Medical Announces 2025 Interim Results | HONG KONG, Aug. 25, 2025 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets... ► Artikel lesen | |
| BACTIGUARD | 2,320 | +5,94 % | Bactiguard Holding AB: Bactiguard Holding AB's interim report second quarter 2025 | Positive EBITDA momentum carried forward in Q2
Second quarter 2025 (April - June)
Total revenue amounted to SEK 52.1 (60.9) million, a decrease of SEK 8.8 million corresponding to 14.4%.
Net sales... ► Artikel lesen | |
| SCIBASE | 0,007 | +34,62 % | SciBase: New Clinical Publication in Karger Dermatology Confirms Reader Studies as Key to Validating Nevisense | STOCKHOLM, Aug. 28, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces the recent publication... ► Artikel lesen |
LIFECARE ASA gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von -0,018 (-2,11 %) liegt der Kurs bei 0,834 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIFECARE ASA finden Sie auf Wallstreet Online.